Nebulized glycosylated caffeic acid phenylether ester attenuation of environmental particulate-induced airway inflammation in horses.
Authors: Rutledge Jessica J, Paegelow Jillian, Ritchey Jerry, Singh Anuradha, Rizzi Theresa, Murray Cynthia, Gilliam Lyndi, Crisman Evan, Williams Natasha J, Holbrook Todd C
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: G-CAPE as a Treatment for Particulate-Induced Airway Inflammation in Horses Environmental dust and mould exposure trigger significant airway inflammation in stabled horses, yet therapeutic options remain limited. Rutledge and colleagues investigated whether nebulised glycosylated caffeic acid phenylether ester (G-CAPE), a polyphenolic compound with known antioxidant properties, could mitigate this inflammatory response in five healthy horses deliberately exposed to poor air quality (straw bedding with mouldy hay for 16 days). Using a crossover design, horses received either 200 mg G-CAPE or placebo vehicle via nebulisation, with respiratory scoring, arterial blood gas analysis, and bronchoalveolar lavage (BAL) fluid sampling performed over 24 hours post-treatment. Within one hour of G-CAPE administration, clinical respiratory scores improved significantly (3.2 ± 0.7 down to 1.6 ± 0.7, p = 0.0013), and at 6 hours post-treatment, BAL neutrophil percentages trended lower in treated horses (9.3% versus 16.9% in controls, though p = 0.1154), suggesting a genuine anti-inflammatory effect despite not reaching statistical significance. For equine professionals managing horses with recurrent airway obstruction or environmental sensitivity, these findings suggest G-CAPE warrants further investigation as a promising nebulised treatment; however, larger multicentre trials are needed to confirm efficacy, optimise dosing, and determine its role within broader respiratory management protocols.
Read the full abstract on PubMed
Practical Takeaways
- •G-CAPE nebulization may offer rapid clinical improvement in respiratory signs within 1 hour of treatment in horses with dust-induced airway inflammation
- •This experimental treatment shows anti-inflammatory potential but requires larger studies before clinical application recommendations can be made
- •Current evidence is preliminary (small sample size, single dose); not yet ready for practice implementation without further investigation
Key Findings
- •Single nebulized dose of G-CAPE significantly reduced clinical respiratory scores from 3.2 to 1.6 within 1 hour post-treatment (p = 0.0013)
- •BAL neutrophil percentage decreased in treated horses (9.3%) versus controls (16.9%) at 6 hours, though difference did not reach statistical significance (p = 0.1154)
- •Arterial blood gas parameters showed no significant differences between G-CAPE-treated and control groups